Company news

Neurizon Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Board Changes

May 8, 2024

Resignation of Dr Michael Thurn & appointment of John Clark

April 22, 2024

Final Ethics Approval for Open-Label MND Extension Study

April 10, 2024

Media clarification

April 2, 2024

Pause in Trading

April 1, 2024

Positive clinical data filed with FDA to support ODD request

March 13, 2024

Appendix 4D & Half-Year Report

February 29, 2024

Positive Phase 1 MEND Study Top-Line Results

February 27, 2024

Presentation - Phase 1 Top-Line Results

February 27, 2024

PharmAust Forms World-Class Scientific Advisory Board

February 21, 2024

FDA Outlines Pathway to Accelerated Approval for MPL in MND

February 15, 2024

Extension Study Begins, Analysis Suggests Survival Benefit

February 13, 2024

Ethics Committee Approval for Open-Label MND Extension Study

January 29, 2024

FDA Provides Clear Feedback for ODD Approval

January 28, 2024

PharmAust Partners with Berry Consultants for MND Phase 2/3

January 15, 2024

FDA Grants PharmAust Pre-IND Meeting

January 1, 2024

FightMND Invites PharmAust to Apply for Phase 2/3 Funding

December 21, 2023

PharmAust Receives R&D Tax Incentive Refund

December 20, 2023

93% take up in Options Offer

December 14, 2023

PharmAust Raises $3.5 Million at a Premium

December 12, 2023

PAA completes Phase 1 and files for Orphan Drug Designation

November 30, 2023

Prospectus & Target Market Determination

November 21, 2023

Appendix 4C and Quarterly Update

October 29, 2023

Options Offer to Existing Listed Option Holders

October 17, 2023

Final MND Patient in Cohort 4 Successfully Completes Dosing

October 12, 2023

Canine Oncology Data Supports Progression to Registration

October 8, 2023

Appendix 4E & Full Year Statutory Accounts

August 31, 2023

Chief Executive Officer Appointment

August 27, 2023

Additional Phase 1 data suggest MPL may inhibit MND

August 21, 2023

Cohort 3 Pharmacokinetics in MND Patients Completed

August 8, 2023

Epichem enters voluntary liquidation

July 31, 2023

MND Trial Successfully Completes 3rd Patient Cohort

July 27, 2023

Canine Trial Update

July 13, 2023

Results show MPL suppresses biomarkers associated with MND

July 11, 2023

Louie the Beagle surpasses one year on MPL

July 5, 2023

MND Biomarkers and Pharmacodynamics Results

July 4, 2023

Motor Neurone Disease Phase 1/2 Clinical Trial Update

June 26, 2023

PharmAust MND Trial Interim Analysis PK Outcomes

June 6, 2023

Motor Neurone Disease Clinical Trial Update

May 21, 2023

Progress update on Phase 1/2 MND interim analysis

May 15, 2023

Independent tests show MPL retains long-term shelf-life

May 9, 2023

MPL has anti-cancer effects across multiple cancer types

May 8, 2023

PharmAust Raises $2.5m via Placement

May 3, 2023

MND Trial Successfully Completes Second Patient Cohort

April 27, 2023

Arrival of additional MPL tablets

April 16, 2023

PharmAust launches international CEO search

April 12, 2023

MND Trial Completes Enrolment of Cohort 2

March 29, 2023

Stable Patient in MND trial reaches 6-months on MPL

March 27, 2023

Canine Cancer Trial Update

March 6, 2023

Interim analysis recommended in MND trial

March 1, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 36 decks. Every deck is listed under its year.